CorMedix Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
CorMedix Inc.
5.56
+0.17 · +3.06%
post 5.59 +0.63%
+14.65%
vs ±13.6% implied · ×1.08
shaded = implied · ▲▼ = realized
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; CorMedix Inc.'s closest co-mover is outside that code.
Closest co-movers · 499d
GWRSGlobal Water Resources×0.11r 0.25Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; CorMedix Inc.'s closest co-mover is outside that code.
Closest co-movers · 499d
GWRSGlobal Water Resources×0.11r 0.25Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $49.6M | 13.80% | +5.97% |
| Deep Track Capital | $49.3M | 13.69% | 0.00% |
| Vanguardindex-like | $24.6M | 6.84% | +0.17% |
| State Streetindex-like | $18.2M | 5.06% | +5.70% |
| Royce & | $17.1M | 4.75% | +15.30% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $49.6M | 13.80% | +5.97% |
| Deep Track Capital | $49.3M | 13.69% | 0.00% |
| Vanguardindex-like | $24.6M | 6.84% | +0.17% |
| State Streetindex-like | $18.2M | 5.06% | +5.70% |
| Royce & | $17.1M | 4.75% | +15.30% |
Bull2
Bear1
Expected move
No implied move.